Year All2024202320222021202020192018201720162014201320112010 May 17, 2017 Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity May 11, 2017 Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity May 4, 2017 Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity April 11, 2017 Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors February 16, 2017 Rhythm Announces Completion of $41 Million Mezzanine Financing November 4, 2016 Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity September 19, 2016 FierceBiotech Names Rhythm as a “Fierce 15” Biotechnology Company of 2016 July 27, 2016 Rhythm Announces “The Genetic Obesity Project” to Expand Understanding of Rare Genetic Disorders of Obesity July 20, 2016 Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity January 7, 2016 Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity
May 17, 2017 Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity
May 11, 2017 Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity
May 4, 2017 Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity
April 11, 2017 Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors
July 27, 2016 Rhythm Announces “The Genetic Obesity Project” to Expand Understanding of Rare Genetic Disorders of Obesity
July 20, 2016 Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
January 7, 2016 Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity
